Drugs / PG-116800
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00067236 | Sep 2003 → Dec 2004 | heart failure, myocardial infarction | Procter and Gamble | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PG-116800 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00067236 ↗ |
| Known as | PG-530742 | “PG-116800 (given as PG-530742)” NCT00067236 ↗ |
| Action | Inhibit | “interferes with the MMP enzyme” NCT00067236 ↗ |
| Route | Oral | “Study of Oral PG-116800 Following a Heart Attack” NCT00067236 ↗ |